Literature DB >> 17849317

Characterization of JC virus in cerebrospinal fluid from HIV-1 infected patients with progressive multifocal leukoencephalopathy: insights into viral pathogenesis and disease prognosis.

Angela Marzocchetti1, Maurizio Sanguinetti, Simona Di Giambenedetto, Antonella Cingolani, Giovanni Fadda, Roberto Cauda, Andrea De Luca.   

Abstract

OBJECTIVES: To analyze virological and immunological features of AIDS-related progressive multifocal leukoencepalophathy (PML) and their association to disease prognosis.
METHODS: In HIV-infected patients with virologically confirmed PML, JC virus (JCV) DNA load and levels of Macrophage Chemoattractant Protein (MCP)-1 were determined in cerebrospinal fluid. JCV genotypes, rearrangements and JCV DNA binding sites for cellular transcription factors were analyzed by sequencing the viral VP1 region and regulatory region (RR).
RESULTS: 45 patients were analyzed: 60% were exposed to highly active antiretroviral therapy (HAART) after PML and 24% before the disease onset. JCV DNA load in cerebrospinal fluid was a strong predictor of patients survival. Lower levels of JCV DNA in cerebrospinal fluid were associated with the following virologic factors: viral genotype 4 (p = 0.043), more rearrangements in the RR (p = 0.046), duplication of RR block B (p = 0.028), and duplication of binding sites for cellular transcription factor NF-1 (p = 0.060). In patients with prior antiretroviral exposure there was a trend towards a higher number of binding sites for cellular transcription factors (p = 0.068). Lower JCV load was also predicted by exposure to HAART (p = 0.010), higher baseline CD4 counts (p = 0.009) and higher cerebrospinal fluid MCP-1 levels (p = 0.036). In a multiple regression model, MCP-1 levels were independently associated with JCV load.
CONCLUSION: HAART leads to a partial immune-mediated control of JCV replication; the virus may tend to escape through the selection of rearrangements in the RR, some associated with enhanced viral replication efficiency, other resulting in multiplication of binding sites for cellular transcription factors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17849317     DOI: 10.1080/13550280701381324

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  37 in total

1.  Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV.

Authors:  J M Tassie; J Gasnault; M Bentata; J Deloumeaux; F Boué; E Billaud; D Costagliola
Journal:  AIDS       Date:  1999-10-01       Impact factor: 4.177

2.  Genotypes of JC virus in East, Central and Southwest Europe.

Authors:  Hansjürgen T Agostini; Alison Deckhut; David V Jobes; Rosina Girones; Günther Schlunck; Marcin G Prost; Carolina Frias; E Pérez-Trallero; Caroline F Ryschkewitsch; Gerald L Stoner
Journal:  J Gen Virol       Date:  2001-05       Impact factor: 3.891

3.  Prolonged survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretroviral therapy.

Authors:  J Gasnault; Y Taoufik; C Goujard; P Kousignian; K Abbed; F Boue; E Dussaix; J F Delfraissy
Journal:  J Neurovirol       Date:  1999-08       Impact factor: 2.643

4.  Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy.

Authors:  Juan Berenguer; Pilar Miralles; Julio Arrizabalaga; Esteban Ribera; Fernando Dronda; Josu Baraia-Etxaburu; Pere Domingo; Manuel Márquez; Francisco J Rodriguez-Arrondo; Fernando Laguna; Rafael Rubio; José Lacruz Rodrigo; J Mallolas; Verónica de Miguel
Journal:  Clin Infect Dis       Date:  2003-04-02       Impact factor: 9.079

5.  Identification of JC virus variants in multiple tissues of pediatric and adult PML patients.

Authors:  J T Newman; R J Frisque
Journal:  J Med Virol       Date:  1999-05       Impact factor: 2.327

6.  Progressive multifocal leukoencephalopathy, HIV, and highly active antiretroviral therapy.

Authors:  P Cinque; S Casari; D Bertelli
Journal:  N Engl J Med       Date:  1998-09-17       Impact factor: 91.245

7.  JC virus type 2B is found more frequently in brain tissue of progressive multifocal leukoencephalopathy patients than in urine from controls.

Authors:  H T Agostini; C F Ryschkewitsch; E J Singer; R W Baumhefner; G L Stoner
Journal:  J Hum Virol       Date:  1998 Mar-Apr

8.  Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: a monocenter observational study with clinical and JC virus load monitoring.

Authors:  J Gasnault; P Kousignian; M Kahraman; J Rahoiljaon; S Matheron; J F Delfraissy; Y Taoufik
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

9.  Human polyomavirus JC virus genome.

Authors:  R J Frisque; G L Bream; M T Cannella
Journal:  J Virol       Date:  1984-08       Impact factor: 5.103

10.  Human polyomavirus JC promoter/enhancer rearrangement patterns from progressive multifocal leukoencephalopathy brain are unique derivatives of a single archetypal structure.

Authors:  G S Ault; G L Stoner
Journal:  J Gen Virol       Date:  1993-08       Impact factor: 3.891

View more
  11 in total

1.  JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy.

Authors:  Chen S Tan; Laura C Ellis; Christian Wüthrich; Long Ngo; Thomas A Broge; Jenny Saint-Aubyn; Janice S Miller; Igor J Koralnik
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

Review 2.  Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain.

Authors:  Michael W Ferenczy; Leslie J Marshall; Christian D S Nelson; Walter J Atwood; Avindra Nath; Kamel Khalili; Eugene O Major
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

3.  JC virus variant associated with cerebellar atrophy in a patient with AIDS.

Authors:  Damien Roux; Marie-Anne Bouldouyre; Séverine Mercier-Delarue; Danielle Seilhean; Anne-Marie Zagdanski; Constance Delaugerre; François Simon; Jean-Michel Molina; Jerôme Legoff
Journal:  J Clin Microbiol       Date:  2011-03-23       Impact factor: 5.948

Review 4.  Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

Authors:  Clemens Warnke; Til Menge; Hans-Peter Hartung; Michael K Racke; Petra D Cravens; Jeffrey L Bennett; Elliot M Frohman; Benjamin M Greenberg; Scott S Zamvil; Ralf Gold; Bernhard Hemmer; Bernd C Kieseier; Olaf Stüve
Journal:  Arch Neurol       Date:  2010-08

Review 5.  [Progressive multifocal leukoencephalopathy. Undesirable side effect of immunotherapy].

Authors:  H-P Hartung; C Warnke; R Hohlfeld; B C Kieseier
Journal:  Nervenarzt       Date:  2009-10       Impact factor: 1.214

6.  False negative PCR despite high levels of JC virus DNA in spinal fluid: Implications for diagnostic testing.

Authors:  Marie L Landry; Tore Eid; Serguei Bannykh; Eugene Major
Journal:  J Clin Virol       Date:  2008-08-12       Impact factor: 3.168

7.  Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era.

Authors:  J L Casado; I Corral; J García; J Martinez-San Millán; E Navas; A Moreno; S Moreno
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-08-16       Impact factor: 3.267

8.  Increased Prevalence of Human Polyomavirus JC Viruria in Chronic Inflammatory Rheumatic Diseases Patients in Treatment with Anti-TNF α: A 18 Month Follow-Up Study.

Authors:  Donatella Maria Rodio; Elena Anzivino; Monica Mischitelli; Anna Bellizzi; Rossana Scrivo; Daniela Scribano; Gianlorenzo Conte; Carla Prezioso; Maria Trancassini; Guido Valesini; Anna Teresa Palamara; Valeria Pietropaolo
Journal:  Front Microbiol       Date:  2016-05-10       Impact factor: 5.640

9.  Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment.

Authors:  Valeria Pietropaolo; Anna Bellizzi; Elena Anzivino; Marco Iannetta; Maria Antonella Zingaropoli; Donatella Maria Rodio; Manuela Morreale; Simona Pontecorvo; Ada Francia; Vincenzo Vullo; Anna Teresa Palamara; Maria Rosa Ciardi
Journal:  J Neurovirol       Date:  2015-05-01       Impact factor: 2.643

Review 10.  Human polyomavirus reactivation: disease pathogenesis and treatment approaches.

Authors:  Cillian F De Gascun; Michael J Carr
Journal:  Clin Dev Immunol       Date:  2013-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.